A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer

Condition(s) studied

Investigational drug(s) / intervention(s)

No treatment is included in this protocol.: No drug intervention or tissue sampling will be included in this study.

Study summary

This is a descriptive observational study in which data are collected in an epidemiological manner. This study is not intended to alter or interfere with the current medical practice of the enrolled patients. Data will be collected in a forward-looking manner. This is a descriptive observational study in which data are collected in an epidemiological manner. This study is not intended to alter or interfere with the current medical practice of the enrolled patients. Data from patients on prior treatment will be collected retrospectively, and data from patients who will be treated later and included in the study will be collected in a prospective manner. The criteria for retrospective collection were consistent with those for prospective collection. Eligible patients will be enrolled after NGS analysis of tumor tissue and informed consent has been obtained. Information required for the study will be collected (every 3 months).

Eligibility

Primary outcome measure(s)

• Progression-Free-Survival — Assessed up to around 4.5 years
  From the time the first patient included in the observational analysis received treatment until disease progression, death due to various causes or censored at the date of last contact
• Overall Survival — Assessed up to around 4.5 years
  From the time the first patient included in the observational analysis received treatment until death due to various causes or censored at the date of last contact

Trial sites (1)

More Hunan Province Tumor Hospital trials in China

Other trials for the same condition